Contineum Therapeutics, Inc. Class A Common Stock
CTNM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $81 | $79 | $0 | $0 |
| Gross Profit | -$81 | -$79 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $10,911 | $13,984 | $13,712 | $13,015 |
| G&A Expenses | $0 | $3,839 | $4,398 | $4,032 |
| SG&A Expenses | $3,940 | $3,839 | $4,398 | $4,032 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$101,788 |
| Operating Expenses | $14,851 | $17,823 | $18,110 | -$84,741 |
| Operating Income | -$14,932 | -$17,902 | -$18,110 | $84,741 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2,140 | $1,862 | $2,120 | -$99,306 |
| Pre-Tax Income | -$12,792 | -$16,040 | -$15,990 | -$14,565 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$12,792 | -$16,040 | -$15,990 | -$14,565 |
| % Margin | – | – | – | – |
| EPS | -0.45 | -0.62 | -0.62 | -0.65 |
| % Growth | 27.4% | 0% | 4.6% | – |
| EPS Diluted | -0.45 | -0.62 | -0.62 | -0.65 |
| Weighted Avg Shares Out | 28,116 | 25,896 | 25,869 | 25,855 |
| Weighted Avg Shares Out Dil | 28,116 | 25,896 | 25,869 | 25,855 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,957 | $2,029 | $2,250 | $2,528 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $81 | $79 | $78 | $75 |
| EBITDA | -$12,711 | -$15,961 | -$18,032 | -$14,490 |
| % Margin | – | – | – | – |